Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rhone-Poulenc Rorer

This article was originally published in The Tan Sheet

Executive Summary

Rhone-Poulenc Fibers and Polymers CEO Michel de Rosen appointed to RPR president and chief operating officer under the company's succession plan for departing RPR Pharmaceuticals President Randy Thurman. In addition, de Rosen will assume the responsibilities of RPR's Office of the President, which was set up during the merger of Rhone-Poulenc and Rorer three years ago and was headed by Thurman and Jean-Jacques Bertrand, president of RPR S.A. Thurman has accepted a position with Corning Labs as chairman and CEO of that company's Metpath/Damon Labs operations and will sit on Corning's board for pharmaceutical and environmental businesses. Bertrand will assume the title of vice chairman and CEO of Pasteur Merieux Serums and Vaccines, effective Jan. 1, 1994. The current CEO of Pasteur Merieux, Alain Audubert, will be promoted to a new position in RPR at the start of 1994.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel